NCT04728334 - A Phase 1 Dose Escalation and Expansion Study of AK117 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 23, 2021

Primary Completion Date

January 25, 2022

Study Completion Date

May 12, 2023

Conditions

Neoplasms Malignant

Interventions

DRUG

AK117

An intravenous (IV) infusion of AK117 as monotherapy. All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal

Trial Locations (1)

200032

FuDan University Shanghai Cancer Center, Shanghai